Video Series

Panelists discuss their final thoughts on the evolving landscape of alopecia areata (AA) treatment, summarizing key takeaways from the discussion and reflecting on future directions for patient care and therapy advancements.

Shaji Kumar, MD, Mayo Clinic, highlights linvoseltamab’s dosing regimen, adverse effect profile, and management strategies. He speaks in particular about cytokine release syndrome, which although common, is typically mild and of short duration, and of proactive prophylaxis to mitigate the risk of severe infection.

Panelists discuss how the introduction of Janus kinase (JAK) inhibitor therapies will likely change treatment algorithms for alopecia areata (AA), with insights on how payers should plan for coverage in the coming years and explore the biggest unmet needs for patients with AA and potential improvements in care.

An expert discusses the personalized approach to treating ROS1-positive non-small cell lung cancer, emphasizing the preference for next-generation TKIs like taletrectinib and repotrectinib due to their CNS activity and efficacy against resistance mutations, particularly G2032R, while highlighting the importance of molecular profiling, avoiding immunotherapy, and considering clinical trials or chemotherapy in later-line settings.

Experts agree that developing value-based care models for atrial fibrillation requires collaborative, data-driven strategies—leveraging clinical pharmacists for personalized medication management and prioritizing stroke prevention and rhythm control—while embracing innovation and workforce redesign to balance quality, cost-effectiveness, and avoid overdiagnosis in an evolving health care landscape.

Experts highlight that applying value-based payment models to atrial fibrillation care requires flexible, team-based approaches focused on reducing hospitalizations, repeat procedures, and stroke, with cardiology groups—supported by pharmacists managing complex therapies—best positioned to deliver comprehensive, quality-driven care that addresses both AFib and its cardiometabolic comorbidities.

Experts note that implantable loop recorders are valuable for detecting infrequent arrhythmias and guiding anticoagulation decisions post-cryptogenic stroke or atrial fibrillation ablation, but due to high costs and limited cost-effectiveness, their use should follow initial short-term monitoring and be tailored to individual patient risk, with ongoing research needed to optimize clinical and economic outcomes.

Panelists discuss how recent clinical trials like ADmirable and DISCOVER intentionally enrolled patients with skin of color (Fitzpatrick types IV-VI), demonstrating similar efficacy and safety profiles for biologics across diverse racial populations, with more than 70% achieving a 75% or greater improvement in the Eczema Area and Severity Index (EASI-75).

Panelists discuss how historical underrepresentation of patients with darker skin tones in clinical trials has limited understanding of treatment efficacy and safety across diverse populations, hampering real-world clinical decision-making.

Shaji Kumar, MD, Mayo Clinic, focuses on the selection, outcomes, and real-world impact of BCMA-targeted bispecific antibodies for multiple myeloma. He emphasizes the factors influencing choice of linvoseltamab, teclistamab, and elranatamab; addresses the impressive results from the LINKER-MM1 trial, which served as the basis for linvoseltamab’s FDA approval; and speaks to linvoseltamab’s new inclusion as a preferred agent in NCCN Guidelines.

Shaji Kumar, MD, Mayo Clinic, discusses the July approval of linvoseltamab, a new bispecific antibody for relapsed myeloma, and how it expands treatment options for patients. He also emphasizes the unique characteristics of linvoseltamab, such as its intravenous administration and flexible dosing schedule.

Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.

Panelists discuss how the Bayesian network meta-analysis showed which Janus kinase (JAK) inhibitors were most effective in reducing Severity of Alopecia Tool (SALT) scores in alopecia areata (AA), highlighting which therapies achieved 50% and 75% improvement, and whether SALT scores are an effective measure of treatment success.

An expert discusses the 2025 NCCN guideline updates for ROS1-positive non-small cell lung cancer, highlighting the inclusion of taletrectinib and repotrectinib as preferred first-line therapies due to their high efficacy and CNS activity, the shift away from older agents like crizotinib and ceritinib, and the critical importance of early molecular testing to guide targeted treatment and avoid immunotherapy in this population.

Experts highlight that while universal screening for subclinical atrial fibrillation remains unsupported by current evidence, targeted screening of high-risk populations using data-driven approaches, combined with proactive management of cardiometabolic risk factors, offers a promising path to improve outcomes and optimize resource use.

Experts emphasize that remote patient monitoring (RPM) is most effective when supported by structured care teams and workflows, with artificial intelligence–enabled tools helping to interpret data and guide timely interventions—making RPM a vital component of personalized, proactive arrhythmia management.

Survivorship care and patient tools like the breast cancer index help patients and doctors curate an individualized survivorship plan for each patient.

Panelists discuss how health care providers need coordinated multidisciplinary care teams, visual resources like databases for eczema in skin of color, peer-to-peer educational sessions, and case-based learning to better recognize and manage atopic dermatitis (AD) across diverse skin tones.

Panelists discuss how treatment access challenges require provider advocacy through peer-to-peer reviews and patient assistance programs, whereas cost-effectiveness evaluation focuses on time to specialist care, therapy duration, and quality-of-life outcomes.

Olivo Adriana, NP, highlights the importance of survivorship care and how providers are utilizing available tools to the best of their ability.

An expert discusses the evolution of ROS1 testing in non-small cell lung cancer, highlighting the shift from FISH-based methods to comprehensive next-generation sequencing of both tissue and plasma, emphasizing RNA-based assays for detecting gene fusions, and stressing the importance of early molecular testing to guide targeted therapy selection and improve patient outcomes.

Panelists discuss the key safety data observed with each of the three Janus kinase (JAK) inhibitors for alopecia areata (AA), highlighting potential adverse effects and how these impact clinical decision-making.

Panelists discuss how ritlecitinib, approved by the FDA in 2023 as the first Janus kinase (JAK) inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and integration into the AA treatment algorithm, while addressing concerns around drug-to-drug interactions.

Experts highlight that well-integrated electronic health records and wearable devices can enhance diagnostic accuracy and patient engagement in arrhythmia care, while emphasizing the importance of combining technology with comprehensive clinical evaluation to guide efficient, personalized testing.

Experts discuss how choosing the right cardiac rhythm monitor involves balancing symptom frequency, patient risk, and device capabilities to ensure efficient, cost-effective, and patient-centered diagnosis while avoiding unnecessary testing.

Panelists discuss how biologic therapy selection depends on disease burden rather than just body surface area (BSA), with monitoring requiring objective measures, patient-reported outcomes, and specialized photography documentation for patients with darker skin tones.

Panelists discuss how patients with darker skin tones often experience delayed diagnosis due to misidentification as fungal infections or other conditions, emphasizing the importance of shared decision-making and patient education about the immune-mediated nature of the disease.

Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment for severe alopecia areata (AA).

Experts discuss how arrhythmia evaluation is tailored based on symptom frequency, severity, and patient risk, using a stepwise approach from short-term to extended monitoring to guide timely and effective diagnosis and management.